Skip to Content

Join the 'Non-Hodgkin's Lymphoma' group to help and get support from people like you.

Non-Hodgkin's Lymphoma News

Related terms: Cancer, Non-Hodgkin's Lymphoma, Histiocytic Lymphoma, Lymphoblastic Lymphoma, Lymphocytic Lymphoma, Lymphoma, Histiocytic, Lymphoma, Lymphoblastic, Lymphoma, Lymphocytic, Lymphoma, Non-Hodgkin's

Immune Therapy Makes Headway Against a Lymphoma

Posted 8 Sep 2016 by

THURSDAY, Sept. 8, 2016 – Genetically engineered immune cells appear capable of eradicating non-Hodgkin lymphoma when coupled with effective chemotherapy, a new early trial finds. In this experimental therapy, white blood cells known as T-cells are removed from the patient's bloodstream. Then they're genetically modified so they can detect and attack cancerous B-cells, another type of white blood cell in which most types of non-Hodgkin lymphoma occur. One-third of 32 patients treated with the modified T-cells experienced a complete remission of their non-Hodgkin lymphoma. And those pretreated with more aggressive chemotherapy did even better, researchers report. "It's a fantastic step forward," said Susanna Greer, director of clinical research and immunology at the American Cancer Society. "It's been difficult to make a lot of progress in lymphoma, especially in non-Hodgkin lymphoma, ... Read more

Related support groups: Non-Hodgkin's Lymphoma, Follicular Lymphoma, Cutaneous T-cell Lymphoma, Burkitt Lymphoma, Diagnosis and Investigation, Waldenström Macroglobulinemia, Mantle Cell Lymphoma, Mycosis Fungoides, Peripheral T-cell Lymphoma

Stem Cell Transplant Can Help HIV Patients Battling Lymphoma: Study

Posted 15 Jun 2016 by

WEDNESDAY, June 15, 2016 – People living with HIV are at high risk for lymphoma, and a new study concludes that stem cell transplant should be standard treatment in these cases. The transplants should be "autologous" – meaning the cells come from the patients themselves, the researchers said. The new findings could challenge the widely held belief that HIV-positive patients are not candidates for this therapy. Instead, the study found that "overall survival for patients with HIV infection after transplant is comparable to that seen in people who were not HIV-infected," said study lead author Dr. Joseph Alvarnas. As his team explained, people with HIV are at increased risk for cancer, even if their infection is well-controlled with antiretroviral drugs. In fact, cancer is now a leading cause of death among HIV patients. The risk of non-Hodgkin lymphoma, specifically in HIV-positive ... Read more

Related support groups: HIV Infection, Lymphoma, Non-Hodgkin's Lymphoma

FDA Medwatch Alert: BiCNU (carmustine for injection): FDA Alert - Counterfeit Product Discovered in Some Foreign Countries

Posted 16 May 2016 by

ISSUE: FDA is informing health care professionals that a counterfeit version of the FDA approved cancer drug, BiCNU (carmustine for injection) 100 mg, has been detected in some foreign countries. There is no indication at this time that counterfeit BiCNU has entered the legitimate U.S. drug supply chain and no indication that any U.S. patients have received counterfeit BiCNU. See the FDA Alert for more information, including product photos and affected lot numbers. BACKGROUND: The authentic product is approved to treat different types of brain cancer, multiple myeloma, and lymphoma (Hodgkin’s and non-Hodgkin’s). BiCNU is manufactured by Emcure Pharmaceuticals Ltd. and distributed in the United States by Heritage Pharmaceuticals Inc. BiCNU is available as a vial of BiCNU and dehydrated alcohol co-packaged together. While the NDC on the outer package of the authentic and counterfeit ver ... Read more

Related support groups: Brain Tumor, Multiple Myeloma, Non-Hodgkin's Lymphoma, Glioblastoma Multiforme, Hodgkin's Lymphoma, Malignant Glioma, BiCNU

FDA Alerts Healthcare Professionals About Clinical Trials with Zydelig (idelalisib) in Combination with other Cancer Medicines

Posted 16 Mar 2016 by

March 14, 2016 – The U.S. Food and Drug Administration is alerting health care professionals about reports of an increased rate of adverse events, including deaths, in clinical trials with the cancer medicine Zydelig (idelalisib) in combination with other cancer medicines. Gilead Sciences, Inc. has confirmed that they are stopping six clinical trials in patients with chronic lymphocytic leukemia, small lymphocytic lymphoma and indolent non-Hodgkin lymphomas. The FDA is reviewing the findings of the clinical trials and will communicate new information as necessary. Health care professionals should be aware that Zydelig is not approved for previously untreated chronic lymphocytic leukemia. Zydelig is currently approved by the FDA for the treatment of: Relapsed chronic lymphocytic leukemia, in combination with rituximab, in patients for whom rituximab alone would be considered ... Read more

Related support groups: Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma, Zydelig

Teva Pharmaceuticals and Eagle Pharmaceuticals Announce FDA Approval of Bendeka (bendamustine hydrochloride) Injection

Posted 10 Dec 2015 by

JERUSALEM & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Dec. 8, 2015-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) today announce that the U.S. Food and Drug Administration (FDA) has approved Bendeka, (bendamustine hydrochloride) injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine. Bendeka is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Efficacy in CLL relative to first-line therapies other than chlorambucil has not been established. “We are thrilled that the FDA has approved Bendeka and are excited for what we believe will be a promising launch with Teva. Importantly, w ... Read more

Related support groups: Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma, Bendamustine, Bendeka

Young Cancer Survivors Often Develop New Malignancies

Posted 6 Oct 2015 by

TUESDAY, Oct. 6, 2015 – Teen and young adult cancer survivors are at increased risk for other cancers later in life, a new study reveals. Researchers analyzed U.S. National Cancer Institute data on people who survived cancers before age 40. They had the most common types of cancers in that age group: leukemia, lymphoma, testicular, ovarian, thyroid, breast, soft tissue and bone cancers. "This is a patient demographic that has been largely overlooked," said senior study author Dr. Robert Goldsby, a professor of pediatrics at the University of California, San Francisco Benioff Children's Hospital. Over 30 years, nearly 14 percent of the survivors were diagnosed with another, different type of cancer. On average, the second cancer occurred within 15 years. Compared to people in the general population, patients successfully treated for cancer between ages 15 and 39 were nearly 60 percent ... Read more

Related support groups: Cancer, Breast Cancer, Hairy Cell Leukemia, Leukemia, Chronic Myelogenous Leukemia (CML), Lymphoma, Basal Cell Carcinoma, Melanoma, Skin Cancer, Chronic Lymphocytic Leukemia (CLL), Ovarian Cancer, Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Stomach Cancer, Cutaneous T-cell Lymphoma, Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Soft Tissue Sarcoma, Acute Lymphocytic Leukemia, Burkitt Lymphoma

Genetically Modified Foods, Herbicides and Human Safety

Posted 19 Aug 2015 by

WEDNESDAY, Aug. 19, 2015 – Farm fields are becoming soaked with increasing amounts of suspected cancer-causing herbicides, thanks to the spread of genetically modified crops that are immune to these chemicals, two researchers contend. They make their argument in a Perspective piece in the Aug. 20 issue of the New England Journal of Medicine. Farmers' use of glyphosate – a weedkiller most commonly known as Roundup – has increased by a factor of more than 250 in the United States, climbing from 0.4 million kilograms in 1974 to 113 million kilograms in 2014, the researchers said. This increase is due to crops such as corn and soybeans that have been genetically altered to be "Roundup-Ready," so they can't be affected by these herbicides, said one of the researchers, Charles Benbrook. He is a research professor at the Washington State University Center for Sustaining Agriculture and ... Read more

Related support groups: Cancer, Poisoning, Non-Hodgkin's Lymphoma, Toxic Reactions Incl Drug and Substance Abuse

2 Drugs Show Promise Against Blood Cancers

Posted 30 May 2015 by

SATURDAY, May 30, 2015 – Two new drugs have shown promise in slowing the march of two incurable blood cancers, researchers report. One drug, ibrutinib, appears to greatly improve standard treatment for patients with recurring chronic-lymphocytic leukemia (CLL), the most common adult leukemia in Western countries. Ibrutinib (Imbruvica) reduced the risk of cancer progression or death by 80 percent when combined with a chemotherapy drug called bendamustine (Treanda) and a targeted therapy drug called rituximab (Rituxan), compared to the other two drugs being used on their own, the researchers found. "We found that if you add ibrutinib to the standard regimen, progression-free survival was significantly improved as a direct result of the ibrutinib," said lead author Dr. Asher Chanan-Khan, a professor of medicine at the Mayo Clinic in Jacksonville, Fla. Meanwhile, the second drug, ... Read more

Related support groups: Rituxan, Rituximab, Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma, Bendamustine, Treanda, Obinutuzumab, Gazyva

Fitness May Help Lower Odds for Non-Hodgkin's Lymphoma

Posted 1 May 2015 by

FRIDAY, May 1, 2015 – A lifetime of vigorous exercise may lower the risk of non-Hodgkin's lymphoma – a form of cancer that affects the lymph nodes, according to a new study. Activities that significantly increase breathing and heart rate appear to have the most benefit, the researchers said. "We know that being physically active reduces the risk of colon cancer and breast cancer, and also leads to a range of other physical and mental health benefits," study author Terry Boyle, a postdoctoral fellow at the University of British Columbia in Canada, said in a news release from the American Association for Cancer Research. "Our findings suggest that people who do vigorous physical activity may also have a lower risk for non-Hodgkin's lymphoma," Boyle added. While this study found an association between intense physical activity and a reduced risk of non-Hodgkin's lymphoma, it wasn't ... Read more

Related support groups: Non-Hodgkin's Lymphoma

FDA Expands Approved Use of Imbruvica for Waldenström’s Macroglobulinemia

Posted 29 Jan 2015 by

January 29, 2015 – The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) for patients with Waldenström’s macroglobulinemia (WM), a rare form of cancer that begins in the body’s immune system. The drug received a breakthrough therapy designation for this use. A type of non-Hodgkin lymphoma, WM usually gets worse slowly over time and causes abnormal blood cells, known as B lymphocytes (B-cells), to grow within the bone marrow, lymph nodes, liver, and spleen. In WM, abnormal B-cells also overproduce a protein known as immunoglobulin M or IgM (macroglobulin) that may lead to excess bleeding, problems with vision and with the nervous system. According to the National Cancer Institute, approximately 70,800 Americans were diagnosed and 18,990 died from non-Hodgkin lymphomas in 2014. Imbruvica works by blocking the enzyme that allows the abnormal B-ce ... Read more

Related support groups: Non-Hodgkin's Lymphoma, Imbruvica, Ibrutinib

Lymphoma Treatment May Harm, Halt Men's Sperm Production

Posted 26 Jul 2014 by

FRIDAY, July 25, 2014 (HealthDay – Treatment for lymphoma may lower men's fertility, new research indicates. Both Hodgkin lymphoma and non-Hodgkin lymphoma, which are cancers of the body's white blood cells, often affect young people who are still in their reproductive years. For men, treatment for these cancers can harm or halt sperm production. Although most men regain their fertility within two years of treatment, the researchers cautioned that men should be counseled about the possibility of this significant side effect before treatment begins. "While many men can look forward to their fertility returning after treatment is over, not all will be so fortunate," Dr. Rebecca Sokol, president of the American Society for Reproductive Medicine, said in a society news release. "It is imperative that prior to the initiation of therapy, counseling and sperm preservation be made available to ... Read more

Related support groups: Lymphoma, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma

FDA Approves Zydelig (idelalisib) for CLL and Lymphoma

Posted 23 Jul 2014 by

July 23, 2014 – The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers. Zydelig is being granted traditional approval to treat patients whose chronic lymphocytic leukemia (CLL) has returned (relapsed). Used in combination with Rituxan (rituximab), Zydelig is to be used in patients for whom Rituxan alone would be considered appropriate therapy due to other existing medical conditions (co-morbidities). Zydelig is the fifth new drug with breakthrough therapy designation to be approved by the FDA and the third drug with this designation approved to treat CLL. The FDA is also granting Zydelig accelerated approval to treat patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) and relapsed small lymphocytic lymphoma (SLL), another type of non-Hodgkin lymphoma. Zydelig is intended to be used in patients who ... Read more

Related support groups: Leukemia, Lymphoma, Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma, Follicular Lymphoma

Zydelig Approved for Three Types of Blood Cancer

Posted 23 Jul 2014 by

WEDNESDAY, July 23, 2014 – Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, including chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic lymphoma (SLL), the FDA said Wednesday in a news release. The approval for the three forms of blood cancer covers instances when the cancer returns despite treatment with at least one other therapy, the agency said. The drug's label will include a boxed warning that the medication could cause liver toxicity, diarrhea, high blood sugar, elevated liver enzymes, high blood triglycerides [a blood fat] and inflammation of the colon (colitis). Other side effects noted during clinical testing included fever, fatigue, nausea, cough, pneumonia, abdominal pain, chills and rash. Zydelig is marketed by Gilead Sciences, based in Foster City, ... Read more

Related support groups: Lymphoma, Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma, Follicular Lymphoma

FDA Approves Beleodaq (belinostat) for Peripheral T-Cell Lymphoma

Posted 3 Jul 2014 by

July 3, 2014 – The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency’s accelerated approval program. PTCL comprises a diverse group of rare diseases in which lymph nodes become cancerous. In 2014, the National Cancer Institute estimates that 70,800 Americans will be diagnosed with NHL and 18,990 will die. PTCL represents about 10 to 15 percent of NHLs in North America. Beleodaq works by stopping enzymes that contribute to T-cells, a type of immune cell, becoming cancerous. It is intended for patients whose disease returned after treatment (relapsed) or did not respond to previous treatment (refractory). “This is the third drug that has been approved since 2009 for the treatment of peripheral T-c ... Read more

Related support groups: Lymphoma, Non-Hodgkin's Lymphoma, Peripheral T-cell Lymphoma

Beleodaq Approved for Aggressive non-Hodgkin Lymphoma

Posted 3 Jul 2014 by

THURSDAY, July 3, 2014 – Beleodaq (belinostat) has been approved by the U.S. Food and Drug Administration to treat peripheral T-Cell lymphoma (PTCL), a rare and aggressive form of non-Hodgkin lymphoma (cancer of the lymph nodes). Some 70,800 Americans will be diagnosed with non-Hodgkin lymphoma this year, of which up to 15 percent will be PTCL, according to U.S. National Cancer Institute estimates. Beleodaq is designed to inhibit immune cells called T-cells from becoming cancerous, the FDA explained Thursday in a news release. The drug is intended for people whose cancer has returned or who didn't respond to a prior therapy, the agency said. Beleodaq's safety and effectiveness were evaluated in clinical studies involving 129 people with PTCL. All were treated with the newly approved drug, and about 26 percent had their cancer disappear or shrink, the FDA said. The most common side ... Read more

Related support groups: Cancer, Lymphoma, Non-Hodgkin's Lymphoma, Peripheral T-cell Lymphoma

Page 1 2 3 Next

Ask a Question

Further Information

Related Condition Support Groups

Mantle Cell Lymphoma, Cutaneous T-cell Lymphoma, Follicular Lymphoma, Waldenström Macroglobulinemia, Peripheral T-cell Lymphoma, Burkitt Lymphoma, Lymphoma

Related Drug Support Groups

methotrexate, Rituxan, rituximab, Imbruvica, Cytoxan, bendamustine, cyclophosphamide, Treanda, ibrutinib, view more... vincristine, Zevalin, Folotyn, cytarabine, Cytosar-U, bleomycin, Bendeka, Cytosar, Oncovin, Bexxar, Methotrexate LPF Sodium, Fludara, Zydelig, Trexall, ibritumomab, fludarabine, Mozobil, teniposide, plerixafor, Bexxar Dosimetric, tositumomab / iodine i 131 tositumomab, Oforta, Bleo 15k, carmustine, mitoxantrone, tositumomab, BexxarTherapeutic, Y-90 Zevalin, Vumon, Vincasar PFS, BiCNU, Novantrone, Gliadel, Cytoxan Lyophilized, Folex PFS, pralatrexate, In-111 Zevalin, idelalisib, Tarabine PFS, Blenoxane, Neosar